New combo therapy shows promise for premenopausal breast cancer patients
NCT ID NCT06009627
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether adding the drug darsilide to standard hormone therapy (exemestane and goserelin) can shrink tumors in premenopausal women with HR-positive, HER2-negative breast cancer. The 119 participants had not responded fully to initial chemotherapy. The main goal was to see how many patients had a significant reduction in tumor size before surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Jie Ge
Tianjin, Tianjin Municipality, 300000, China